Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data. (19th August 2020)

• Record Type: Journal Article
• Authors: Adambekov, Shalkar; Lopa, Samia; Edwards, Robert P.; Lemon, Lara; Wang, Shu; Taylor, Sarah E.; Orr, Brian; Linkov, Faina
• Is Part Of: Cancer medicine. Volume 9:Number 20(2020)
• Page Start: 7388
• Page End: 7397
• Publication Date: 2020-08-19
• Subjects: carcinoma -- drug therapy -- intraperitoneal chemotherapy -- ovarian epithelial -- recurrence -- registries -- survival; 616.994005
• DOI: 10.1002/cam4.3340
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: Intraperitoneal/intravenous chemotherapy (IP/IV) was associated with improved survival for ovarian cancer (OC) patients in several randomized clinical trials. However, the uptake of IP/IV in clinical practice is varied due to conflicting evidence about its impact on survival and recurrence. The aim of this study was to explore the uptake of IP/IV treatment and to evaluate its impact on survival and recurrence in OC patients. Methods: Demographic and clinical information on OC patients (N = 2916) who underwent treatment for OC between 2000 and 2017 was obtained from the large healthcare system cancer registry. Duplicate records, grade 1, rare (eg, gelatinous carcinoma), and non‐epithelial (eg, granulosa cell carcinoma) tumors were excluded. Kaplan‐Meier survival curves were constructed to compare 5‐ and 10‐year survival based on the chemotherapy type, surgery type, and stage. Multivariable Gray's piecewise constant time‐varying coefficient models were fitted to evaluate the effect of IP/IV on adjusted hazard ratio (AHR) of OC survival and recurrence adjusting for potential confounders. Results: The final sample consisted of 1846 OC patients, 14% (250/1846) of which received IP/IV chemotherapy. IP/IV was significantly associated with improved 10‐year survival ( P < .001). Multivariable Gray's model demonstrated that IP/IV therapy significantly reduced the AHR of death (AHR = 0.39‐1.07, P < .001) with the beneficial effect gradually declining over time. Use of IP/IV chemotherapy had no impact on OC recurrence. Conclusions: These findings demonstrated that only a small fraction of eligible patients underwent IP/IV chemotherapy. We report a significant 10‐year survival, but not necessarily recurrence benefit is associated with IP/IV chemotherapy compared to IV only, suggesting the need for novel ways of identifying patients who may benefit from IP/IV chemotherapy. Abstract : Only one of seven eligible patients underwent intraperitoneal chemotherapy in our large heterogenous health system. Intraperitoneal chemotherapy use has been associated with improved 10‐year survival, but not necessarily recurrence benefit compared to intravenous chemotherapy.